ADMA BIOLOGICS, INC. (ADMA): debt financing — ADMA Biologics Q2 revenue up 29% underlying; launches yield-enhanced IG mfg

ADMA BIOLOGICS, INC.

2025-Q2 EPS reported $0.25 revenue$236,786,000

Q2 2025 total revenue $122.0M, up 14% YoY (29% excluding $12.6M prior-year Medicaid reversal).
GAAP net income $34.2M; Adjusted EBITDA $50.8M, up 59% YoY underlying.
Began commercial-scale yield-enhanced IG manufacturing delivering 20%+ output gain.
Closed $300M J.P. Morgan-led financing ($75M term loan, $225M revolver) replacing Ares debt.
Reaffirmed FY2025-2026 guidance; pre-2030 revenue target $1.1B+; repurchased $15M stock.

item 1.01 item 1.02 item 2.02 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

ADMA BIOLOGICS, INC. incurred term loan of $75 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.

Instrument: term loan
Principal: $75 million
Counterparty: JPMorgan Chase Bank, N.A.
Rate: 150 basis points to 200 basis points over the alternate base rate and 250 basis
Maturity: August 5, 2028
Event: incurrence

Exact text from the filing

The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the "Term Loan Facility") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the "Revolving Facility").

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

ADMA BIOLOGICS, INC. incurred revolving credit of $225 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.

Instrument: revolving credit
Principal: $225 million
Counterparty: JPMorgan Chase Bank, N.A.
Rate: 150 basis points to 200 basis points over the alternate base rate and 250 basis
Maturity: August 5, 2028
Event: incurrence

Exact text from the filing

The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the "Term Loan Facility") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the "Revolving Facility").

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

ADMA BIOLOGICS, INC. incurred credit facility of $300 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.

Instrument: credit facility
Principal: $300 million
Counterparty: JPMorgan Chase Bank, N.A.
Rate: 150 basis points to 200 basis points over the alternate base rate and 250 basis
Maturity: August 5, 2028
Event: incurrence

Exact text from the filing

into a Credit Agreement (the “Credit Agreement”), with the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the “Term Loan Facility”) and (b) a revolving credit

View on SEC.gov

317 debt financings filed in the last 30 days. Browse all debt financings →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-25-029143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.